» Articles » PMID: 32376656

Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy

Abstract

Purpose: Patients with colorectal cancer with peritoneal metastases (CRPMs) have limited treatment options and the lowest colorectal cancer survival rates. We aimed to determine whether organoid testing could help guide precision treatment for patients with CRPMs, as the clinical utility of prospective, functional drug screening including nonstandard agents is unknown.

Experimental Design: CRPM organoids (peritonoids) isolated from patients underwent parallel next-generation sequencing and medium-throughput drug panel testing to identify specific drug sensitivities for each patient. We measured the utility of such a service including: success of peritonoid generation, time to cultivate peritonoids, reproducibility of the medium-throughput drug testing, and documented changes to clinical therapy as a result of the testing.

Results: Peritonoids were successfully generated and validated from 68% (19/28) of patients undergoing standard care. Genomic and drug profiling was completed within 8 weeks and a formal report ranking drug sensitivities was provided to the medical oncology team upon failure of standard care treatment. This resulted in a treatment change for two patients, one of whom had a partial response despite previously progressing on multiple rounds of standard care chemotherapy. The barrier to implementing this technology in Australia is the need for drug access and funding for off-label indications.

Conclusions: Our approach is feasible, reproducible, and can guide novel therapeutic choices in this poor prognosis cohort, where new treatment options are urgently needed. This platform is relevant to many solid organ malignancies.

Citing Articles

The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study.

Guchelaar N, de Neijs M, Noordman B, Graaf H, van Hellemond I, van der Sluis P EClinicalMedicine. 2025; 81:103109.

PMID: 40026831 PMC: 11872448. DOI: 10.1016/j.eclinm.2025.103109.


Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications.

Paul C, Yankaskas C, Shahi Thakuri P, Balhouse B, Salen S, Bullock A Sci Rep. 2025; 15(1):3933.

PMID: 39890889 PMC: 11785764. DOI: 10.1038/s41598-025-86979-9.


Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines.

Razumovskaya A, Silkina M, Poloznikov A, Kulagin T, Raigorodskaya M, Gorban N Front Mol Biosci. 2025; 12:1531175.

PMID: 39886381 PMC: 11774744. DOI: 10.3389/fmolb.2025.1531175.


Trends in Colorectal Cancer Peritoneal Metastases Research: A Comprehensive Bibliometric Analysis.

Zhang Y, Jin Z, Wang Z, Yan L, Liu A, Li F J Gastrointest Cancer. 2025; 56(1):51.

PMID: 39847239 DOI: 10.1007/s12029-025-01176-1.


A Two-Step Protocol for Isolation and Maintenance of Lung Cancer Primary 3D Cultures.

Strocchi S, Santandrea G, Zanetti E, Verna G, Cusenza V, Nicoli D Cancers (Basel). 2025; 17(1.

PMID: 39796658 PMC: 11718983. DOI: 10.3390/cancers17010027.


References
1.
Franko J, Shi Q, Meyers J, Maughan T, Adams R, Seymour M . Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016; 17(12):1709-1719. DOI: 10.1016/S1470-2045(16)30500-9. View

2.
Alzahrani N, Valle S, Fisher O, Sugarbaker P, Yonemura Y, Glehen O . Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. J Surg Oncol. 2018; 119(3):336-346. DOI: 10.1002/jso.25277. View

3.
Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

4.
Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View

5.
Sato T, Stange D, Ferrante M, Vries R, van Es J, van den Brink S . Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 2011; 141(5):1762-72. DOI: 10.1053/j.gastro.2011.07.050. View